Portugal now part of MRA with FDA
Recommendation
27/28 May 2026
Batch Manufacturing Documents: from Preparation to Operational Excellence
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
After a positive assessment, the US Food and Drug Administration (FDA) has approved Portugal to be fully covered by the current EU-FDA Mutual Recognition Agreement (MRA) of GMP inspections of human manufacturers.
The total number of countries accepted by the FDA is now 15: Croatia, France, Italy, Malta, Spain, Sweden, United Kingdom, Czech Republic, Greece, Austria, Hungary, Romania, Lithuania, Ireland and Portugal.
Other EU member states will be added as their evaluation is completed by the US. According to a previous EMA press release, "Plans for the agreement to be operational in all EU Member States by 15 July 2019 are on track."
Source: EMA Press Release entitled "Portugal to also benefit from EU-US mutual recognition agreement for inspections".
Related GMP News
22.04.2026No Validation, No Controls, and No Suitable Rooms and Equipment - Extensive Warning Letter
25.03.2026FDA Warning Letter highlights once again: Weaknesses in the CAPA Process remain a key GMP Issue
18.03.2026FDA Issues Draft Guidance on Responding to Form 483 Observations
28.01.2026What is the Procedure for GMP Inspections (EU GMP inspections and FDA Inspections)?
21.01.2026FDA Warning Letter highlights critical Failures in Supplier and Quality Oversight
19.01.2026GMP Auditor Association Developments September through December 2025